www.cynvenio.com



A New Tool to Monitor Breast Cancer Survivors

- ClearID[™] is an innovative blood test that sequences the tumor and looks for cancer associated mutations
- Genetic alterations that are found in the blood are matched to current therapeutic options as well as ongoing clinical trials
- Unlike radiographic tools that look for physical changes in the tumor, ClearID looks for the genomic alterations associated with disease
- A simple blood draw, compared to risky and invasive tissue biopsy



ClearID: The Solution

Clear ID detects genetic alterations in cancer cells and monitors the level of these alterations to help guide treatment decisions in four specific applications:

- Distance of the static breast cancer disease
- Solution when there is a lack of tissue to biopsy or QNS (quantity not sufficient)
- Longitudinal monitoring to assess clinical response to therapy or identifying changes/ emergence of new genomic alterations
- Recurrence monitoring for high risk breast cancer survivors

ClearID complements the Standard of Care (NCCN Guidelines), to alert physicians when aggressive surveillance is required.

ORDERING INFORMATION

For more information and to find out how to order ClearID, give us a call or send us an email.

Call: (888) 885-1172 (805) 855-2050 Email: clientservices@cynvenio.com

The Results

ClearID results are summarized in a patient-specific

genomic report that includes leading-edge, clinically relevant knowledge on current and experimental treatments and diagnostics.

Summary test reports are available within 3-10 days of sample processing.

	ClearID		sis Repr	at				cynven
State State <th< th=""><th>Patient Kr Drite familier</th><th>Tablesia Maria</th><th></th><th>American Tapa Lateratura Macalum</th><th>aviges</th><th></th><th></th><th></th></th<>	Patient Kr Drite familier	Tablesia Maria		American Tapa Lateratura Macalum	aviges			
Note: Note: <th< th=""><th>1 (maple in</th><th></th><th></th><th></th><th>-</th><th></th><th>una lalantifast</th><th></th></th<>	1 (maple in				-		una lalantifast	
Karl N	NEXT.	LINE CALLER	1940 1940	4052.	-	-		
The balancement of the same and experient particular devices of the same of th			40	etr.	2	70	include using the includes. This is other sub-cost toll	art productions. 1953 courts appelly fragmentary data in accellant function. Matter
	The Description	a sectores		r men te dete			na d'enamente	
			10000	the spectra spin			- 3 to prove the second	
Enclosed agest in Wester Printerson, MI, Berlin Closely - Link MERCET R. & Longer, 117								10000



© 2014 Cynvenio Biosystems, Inc. All rights reserved.

Cynvenio Biosystems, Inc. 2260 Townsgate Road Westlake Village, CA 91361 Toll-free (North America): 1.888.885.1172 Tel.: 805.855.2050 Fax: 805-855-2022 Email: clientservices@cynvenio.com

